Published in Lancet on October 23, 2009
Safety Study in Subjects With Leber Congenital Amaurosis | NCT00516477
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis | NCT00999609
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet (2014) 4.24
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol (2011) 3.79
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med (2015) 2.68
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet (2010) 2.18
Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet (2014) 2.16
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest (2010) 2.13
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
The retinal pigment epithelium in health and disease. Curr Mol Med (2010) 1.87
NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet (2012) 1.86
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology (2013) 1.85
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res (2010) 1.81
Gene therapy finds its niche. Nat Biotechnol (2011) 1.70
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res (2012) 1.66
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci (2012) 1.47
Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci (2011) 1.46
Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther (2012) 1.44
Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest (2010) 1.39
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med (2010) 1.35
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther (2010) 1.35
Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet (2012) 1.31
Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther (2011) 1.28
Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther (2010) 1.26
Innate Immune Responses to AAV Vectors. Front Microbiol (2011) 1.24
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther (2010) 1.21
Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes. Hum Mutat (2010) 1.21
Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. Sci Transl Med (2010) 1.20
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Cone opsin determines the time course of cone photoreceptor degeneration in Leber congenital amaurosis. Proc Natl Acad Sci U S A (2011) 1.18
New insights into retinoid metabolism and cycling within the retina. Prog Retin Eye Res (2012) 1.16
Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther (2011) 1.16
CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype. Gene Ther (2014) 1.15
Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A (2011) 1.14
Biotech in a blink. Nat Biotechnol (2010) 1.13
Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Hum Mol Genet (2010) 1.13
Two decades of clinical gene therapy--success is finally mounting. Discov Med (2010) 1.13
Therapeutic challenges to retinitis pigmentosa: from neuroprotection to gene therapy. Curr Genomics (2011) 1.10
Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol (2013) 1.10
The gene therapy journey for hemophilia: are we there yet? Blood (2012) 1.10
Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther (2012) 1.09
Concise Review: Patient-Specific Stem Cells to Interrogate Inherited Eye Disease. Stem Cells Transl Med (2015) 1.08
Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol Ther (2014) 1.08
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol (2011) 1.08
Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gene Ther Methods (2014) 1.08
Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression. Mol Ther (2012) 1.08
Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther (2011) 1.07
Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther (2012) 1.06
Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther (2011) 1.05
A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases. Mol Vis (2011) 1.05
Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials (2014) 1.05
Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev (2016) 1.05
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids (2012) 1.05
Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med (2013) 1.04
Gene correction by homologous recombination with zinc finger nucleases in primary cells from a mouse model of a generic recessive genetic disease. Mol Ther (2010) 1.04
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Adeno-associated virus: a key to the human genome? Future Virol (2010) 1.03
Current concepts in the treatment of retinitis pigmentosa. J Ophthalmol (2010) 1.03
Genetic therapy for the nervous system. Hum Mol Genet (2011) 1.03
Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med (2011) 1.02
Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum Gene Ther (2011) 1.02
Gene therapy matures in the clinic. Nat Biotechnol (2012) 1.02
Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther (2011) 0.98
The physiological impact of microRNA gene regulation in the retina. Cell Mol Life Sci (2012) 0.98
Altered expression of retinal molecular markers in the canine RPE65 model of Leber congenital amaurosis. Invest Ophthalmol Vis Sci (2010) 0.98
Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics (2014) 0.98
Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patients. Biomed Eng Online (2012) 0.98
Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations. J Inherit Metab Dis (2010) 0.97
Whirlin replacement restores the formation of the USH2 protein complex in whirlin knockout photoreceptors. Invest Ophthalmol Vis Sci (2011) 0.97
Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res (2014) 0.97
Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis. Invest Ophthalmol Vis Sci (2012) 0.97
Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells. Biomaterials (2011) 0.96
Retinal gene therapy coming of age. Hum Gene Ther (2013) 0.96
Histopathology and functional correlations in a patient with a mutation in RPE65, the gene for retinol isomerase. Invest Ophthalmol Vis Sci (2011) 0.95
Gene therapy for Leber congenital amaurosis: advances and future directions. Graefes Arch Clin Exp Ophthalmol (2012) 0.95
Rescue of enzymatic function for disease-associated RPE65 proteins containing various missense mutations in non-active sites. J Biol Chem (2014) 0.95
Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res (2014) 0.94
Retinal dystrophies and gene therapy. Eur J Pediatr (2011) 0.94
Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. Hum Gene Ther Methods (2012) 0.94
Diagnostic challenges in retinitis pigmentosa: genotypic multiplicity and phenotypic variability. Curr Genomics (2011) 0.94
Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet (2016) 0.94
Two novel CRX mutant proteins causing autosomal dominant Leber congenital amaurosis interact differently with NRL. Hum Mutat (2010) 0.93
Halting progressive neurodegeneration in advanced retinitis pigmentosa. J Clin Invest (2015) 0.93
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest (2013) 0.92
Gene therapy in the cornea: 2005--present. Prog Retin Eye Res (2011) 0.92
MicroRNA-restricted transgene expression in the retina. PLoS One (2011) 0.92
Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat Rev Drug Discov (2013) 0.92
Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin Biol Ther (2015) 0.92
Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther (2014) 0.92
Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol (2013) 0.91
Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol (2011) 0.91
Test-Retest Intervisit Variability of Functional and Structural Parameters in X-Linked Retinoschisis. Transl Vis Sci Technol (2014) 0.91
CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol Ther (2013) 0.91
Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci (2014) 0.91
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet (1998) 7.57
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res (2008) 5.90
Amplification and kinetics of the activation steps in phototransduction. Biochim Biophys Acta (1993) 4.80
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A (2005) 4.67
RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci U S A (2005) 4.61
Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell (2005) 4.51
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol (1985) 2.98
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72
Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci (2007) 2.69
Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci (2000) 2.67
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57
In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther (2004) 2.56
Leber congenital amaurosis. Mol Genet Metab (1999) 2.52
Latency of the pupil light reflex: sample rate, stimulus intensity, and variation in normal subjects. Invest Ophthalmol Vis Sci (2003) 2.02
Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci (2006) 2.01
Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa. Doc Ophthalmol (2004) 1.94
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
A gene network regulating lysosomal biogenesis and function. Science (2009) 7.17
Comparative analysis of RNA-Seq alignment algorithms and the RNA-Seq unified mapper (RUM). Bioinformatics (2011) 6.20
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 5.24
Comparison of preschool vision screening tests as administered by licensed eye care professionals in the Vision In Preschoolers Study. Ophthalmology (2004) 4.98
A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol (2011) 4.84
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 4.67
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
Human chromosome 21 gene expression atlas in the mouse. Nature (2002) 4.36
Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med (2005) 4.27
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
The proteome of the mouse photoreceptor sensory cilium complex. Mol Cell Proteomics (2007) 3.53
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 3.52
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe (2013) 3.21
Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet (2008) 3.21
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature (2012) 3.08
TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet (2011) 3.06
MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab (2010) 2.99
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol (2006) 2.76
Spontaneous activity of opsin apoprotein is a cause of Leber congenital amaurosis. Nat Genet (2003) 2.76
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72